| Neuroblastoma origin and therapeutic targets for immunotherapy IV Kholodenko, DV Kalinovsky, II Doronin, SM Deyev, RV Kholodenko Journal of immunology research 2018 (1), 7394268, 2018 | 160 | 2018 |
| Ganglioside GD2 in reception and transduction of cell death signal in tumor cells II Doronin, PA Vishnyakova, IV Kholodenko, ED Ponomarev, ... BMC cancer 14, 1-17, 2014 | 112 | 2014 |
| Antibody fragments as potential biopharmaceuticals for cancer therapy: success and limitations RV Kholodenko, DV Kalinovsky, II Doronin, ED Ponomarev, ... Current Medicinal Chemistry 26 (3), 396-426, 2019 | 104 | 2019 |
| RNA sequencing-based identification of ganglioside GD2-positive cancer phenotype M Sorokin, I Kholodenko, D Kalinovsky, T Shamanskaya, I Doronin, ... Biomedicines 8 (6), 142, 2020 | 25 | 2020 |
| Multimerization through pegylation improves pharmacokinetic properties of scFv fragments of GD2-specific antibodies IV Kholodenko, DV Kalinovsky, EV Svirshchevskaya, II Doronin, ... Molecules 24 (21), 3835, 2019 | 24 | 2019 |
| Peptogrid—rescoring function for autodock vina to identify new bioactive molecules from short peptide libraries AO Zalevsky, AS Zlobin, VR Gedzun, RV Reshetnikov, ML Lovat, ... Molecules 24 (2), 277, 2019 | 16 | 2019 |
| Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors DV Kalinovsky, AV Kibardin, IV Kholodenko, EV Svirshchevskaya, ... Journal for ImmunoTherapy of Cancer 10 (6), 2022 | 15 | 2022 |
| Preparation of Fab-Fragments of GD2-Specific Antibodies and Analysis of Their Antitumor Activity In Vitro II Doronin, IV Kholodenko, IM Molotkovskaya, RV Kholodenko Bulletin of experimental biology and medicine 154, 658-663, 2013 | 11 | 2013 |
| Minibody-based and ScFv-based antibody fragment-drug conjugates selectively eliminate GD2-positive tumor cells DV Kalinovsky, IV Kholodenko, AV Kibardin, II Doronin, ... International Journal of Molecular Sciences 24 (2), 1239, 2023 | 10 | 2023 |
| Peptide LCGA-17 attenuates behavioral and neurochemical deficits in rodent models of PTSD and depression AV Malyshev, IA Sukhanova, VM Ushakova, YA Zorkina, OV Abramova, ... Pharmaceuticals 15 (4), 462, 2022 | 9 | 2022 |
| In silico Screening and Behavioral Validation of a Novel Peptide, LCGA-17, With Anxiolytic-Like Properties AV Malyshev, IA Sukhanova, AS Zlobin, VR Gedzun, VV Pavshintsev, ... Frontiers in Neuroscience 15, 705590, 2021 | 9 | 2021 |
| Chitosan nanoparticles targeted to the tumor-associated ganglioside GD2 AA Zubareva, AA Boyko, IV Kholodenko, FN Rozov, MV Larina, TK Aliev, ... Russian Journal of Bioorganic Chemistry 42, 532-545, 2016 | 9 | 2016 |
| Tumor models in the study of cancer diseases IV Kholodenko, II Doronin, RV Kholodenko Immunology [Immunologiya] 34 (5), 282-286, 2013 | 9 | 2013 |
| Caspases participation in cell death induced by the GD2-specific antibodies PA Vishnyakova, II Doronin, IV Kholodenko, DY Ryazantsev, ... Russian Journal of Bioorganic Chemistry 40, 279-287, 2014 | 8 | 2014 |
| Involvement of actin filaments in the cytotoxic effect of GD2-specific antibodies II Doronin, IV Kholodenko, AA Zubareva, KN Yarygin, SM Deev, ... Bulletin of Experimental Biology and Medicine 166, 541-547, 2019 | 5 | 2019 |
| Antitumor activity of GD2-specific antibodies and their Fab-fragments in the mouse tumor model IV Kholodenko, II Doronin, PA Vishnyakova, EL Bolkhovitina, ... Immunologiya (Russia) 34, 199-203, 2013 | 5 | 2013 |
| P. 068 Stress-protective effects of a novel peptide GABAergic system modulator in animal models of anxiety, depression and post-traumatic stress disorder A Malyshev, C Haile, I Sukhanova, I Doronin, V Gedzun, N Mitkin, ... European Neuropsychopharmacology 40, S44-S45, 2020 | 2 | 2020 |
| P. 519 Behavioral effect of novel peptide modulators of GABAergic system in zebrafish model A Malyshev, I Doronin, V Gedzun, I Sukhanova, E Razumkina, ... European Neuropsychopharmacology 29, S366-S367, 2019 | 2 | 2019 |
| The novel peptide chm-273s has therapeutic potential for metabolic disorders: evidence from in vitro studies and high-sucrose diet and high-fat diet rodent models NA Mitkin, VV Pavshintcev, IA Sukhanova, II Doronin, GA Babkin, ... Pharmaceutics 14 (10), 2088, 2022 | 1 | 2022 |
| The approach for selection optimal combinations of chemotherapy drugs with GD2-specific antibodies for the effective elimination of GD2-positive tumor cells II Doronin, IV Kholodenko, AA Buzdin, MI Sorokin, TV Shamanskaya, ... Febs Open Bio 9, 339-339, 2019 | 1 | 2019 |
